Etoposide

Etoposide is a semisynthetic derivative of podophyllotoxin with antineoplastic properties; it interferes with the function of topoisomerase II thus inhibiting DNA synthesis, and is most active against cells in the late S and G2 phases of the cell cycle. It is a semisynthetic drug derived from the resin of the Podophyllum peltatum (mandrake root or May apple).
It is used, usually in combination with other antineoplastics, in the treatment of tumours of the testis, small cell cancer of the lung, and in acute leukaemias. It has also been tried in other solid tumours including those of the brain, gastrointestinal tract, ovary, and thymus, and some childhood neoplasms; in lymphomas, and in the treatment of Kaposi's sarcoma associated with AIDS.

Etoposide’s innovator is Novartis-Global and is known by the brand name Vepesid.

Etoposide is a cytocidal agent that is active during the G2 phase of the cell cycle. Etoposide binds to a complex of DNA and topoisomerase II. Topoisomerase II is an enzyme that coils and uncoils DNA and also examines and repairs faulty sections of DNA. Etoposide stabilizes the DNA and topoisomerase II complex and prevent further progression in the cell cycle. DNA strand breaks develop, and the cell undergoes apoptosis (programmed cell death).

Etoposide appears in the following formulation and dosage:
Capsules: 50 mg
Intravenous Solution: 20 mg/ml

General data on Etoposide Active Pharmaceutical Ingredient

CAS Registry: 33419-42-0
ATC: L01CB01
Molecular Formula: C29H32O13
Molecular Weight: 588.6
Pharmacopoeias: In Chin., Eur., Int., Jpn, and US.

Ph. Eur. 5.5: Etoposide is a white or almost white, crystalline powder. Etoposide is practically insoluble in water; slightly soluble in alcohol and in dichloromethane; sparingly soluble in methyl alcohol.

USP 30: Etoposide is a fine, white to off-white, crystalline powder. Etoposide is very slightly soluble in water; slightly soluble in alcohol, in chloroform, in dichloromethane, and in ethyl acetate; sparingly soluble in methyl alcohol.

TAPI's Etoposide Pharmaceutical Ingredient

TAPI's Etoposide Active Pharmaceutical Ingredient is produced in Sicor- Società Italiana Corticosteroidi S.r.l Santhià site in santhia (Vercelli), Italy.

Etoposide is a highly potent active pharmaceutical ingredient. Etoposide belongs to the hormone contraceptive and replacement therapy group of drugs. These drugs are highly potent active pharmaceutical ingredients that need special handle in production or preparation. As a highly potent drug, Etoposide is considered to be small volume Active Pharmaceutical Ingredient.

TAPI provides full service on Etoposide and other APIs in our portfolio. We provide information on TAPI's Etoposide, the regulatory compliance with various health regulations and documentation. Contact us today for further inquiries and samples and kilograms availability information for TAPI's Etoposide.

TAPI is a world leading developer and manufacturer of highly potent drugs used by innovative and generic companies to formulate their final dosage medications. TAPI highly potent manufacturing plants are located mainly in Italy (Sicor S.r.l. ) and Mexico (Sicor de Mexico) . TAPI highly potent active pharmaceutical ingredients, such as Etoposide, are used in oral, parenteral, topical and inhalation therapies; and most fall in four classes: Steroids, Oncolytics, Hormones, Non-depolarizing muscle relaxants, Immunosuppressants.

2008 Available DMF: U.S. DMF, EU CTD, CEP, Japan DMF and India DMF.

Other products, in the group of ANTINEOPLASTIC AGENTS - Miscellaneous antineoplastics available on TAPI's portfolio are: Bicalutamide,Bortezomib,Fludarabine Phosphate,Fluorouracil and Pemetrexed Diacid.

Contact us today for information on TAPI's Etoposide  and other highly potent Active Pharmaceutical Ingredients.

Legal Note

Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products  that  Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).

*TAPI stands for Teva's Active Pharmaceutical Ingredients